A biodegradable, porous biomaterial that creates a localized environment for immune-cell recruitment, activation, and expansion — programming antitumor immunity directly inside the patient.
Implanted beside the tumor, SymphNode acts locally — recruiting T cells, boosting the activation of tumor-specific T cells, and suppressing regulatory T cells (Tregs) through sustained release of immunomodulatory agents.
Draws the patient’s own T cells into the scaffold to fight the tumor.
Enhances the activation of tumor-specific T cells.
Counters regulatory T cells that shield tumors from immune attack.
Three steps, from placement beside the tumor to an antitumor immune response.
SymphNode is implanted next to a solid tumor — potentially at the time of biopsy or surgical removal, fitting into procedures patients may already undergo.
Its porous, biodegradable structure gives immune cells a three-dimensional space to enter. Around the tumor, regulatory T cells (Tregs) keep the immune system from attacking.
Through sustained release of immunomodulatory agents, SymphNode recruits the patient’s own T cells into the scaffold.
Because it works locally, it’s designed to limit the systemic side effects of body-wide immunotherapy. No cells are removed or engineered outside the body.
Acting as a synthetic lymph node, SymphNode boosts the activation of tumor-specific T cells, which leave the scaffold to attack the tumor.
At the same time, it suppresses regulatory T cells that shield the tumor. The goal is durable, systemic antitumor immunity that also targets residual cancer cells and limits recurrence or metastasis.
Conventional approaches rely on systemic drugs or complex manipulation of immune cells outside the body. SymphNode works with the body’s existing immune cells.
The immunology and engineering principles that guide our platform.